Adc Therapeutics Sa Stock Today
| ADCT Stock | USD 2.26 0.04 1.80% |
Performance0 of 100
| Odds Of DistressOver 68
|
ADC Therapeutics is selling for under 2.26 as of the 28th of November 2024; that is 1.80% up since the beginning of the trading day. The stock's last reported lowest price was 2.21. ADC Therapeutics has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for ADC Therapeutics SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of September 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Technology Hardware & Equipment | IPO Date 16th of March 1979 | Category Healthcare | Classification Information Technology |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. The company has 96.69 M outstanding shares of which 3.17 M shares are presently shorted by private and institutional investors with about 9.62 trading days to cover. More on ADC Therapeutics SA
Moving against ADC Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ADC Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Christopher Martin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Communications Equipment, Technology Hardware & Equipment, Information Technology, NYSE Composite, Information Technology, Communications Equipment, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsADC Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ADC Therapeutics' financial leverage. It provides some insight into what part of ADC Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADC Therapeutics SA (ADCT) is traded on New York Stock Exchange in USA. It is located in BiopOle, Epalinges, Switzerland, 1066 and employs 273 people. ADC Therapeutics is listed under Communications Equipment category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 214.65 M. ADC Therapeutics conducts business under Communications Equipment sector and is part of Information Technology industry. The entity has 96.69 M outstanding shares of which 3.17 M shares are presently shorted by private and institutional investors with about 9.62 trading days to cover.
ADC Therapeutics SA currently holds about 376.78 M in cash with (118.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ADC Therapeutics Probability Of Bankruptcy
Ownership AllocationADC Therapeutics secures a total of 96.69 Million outstanding shares. Over half of ADC Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ADC Ownership Details
ADC Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 953.2 K | |
| Vantage Consulting Group Inc. | 2024-06-30 | 850.7 K | |
| Millennium Management Llc | 2024-06-30 | 816.5 K | |
| Blue Owl Capital Holdings Lp | 2024-09-30 | 733.6 K | |
| Vanguard Group Inc | 2024-09-30 | 539.4 K | |
| Northern Trust Corp | 2024-09-30 | 481 K | |
| Gcm Grosvenor Holdings, Llc | 2024-09-30 | 410.9 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 284.2 K | |
| Two Sigma Investments Llc | 2024-09-30 | 245.3 K | |
| Redmile Group, Llc | 2024-09-30 | 15.7 M | |
| Prosight Management, Lp | 2024-06-30 | 9.6 M |
ADC Therapeutics Historical Income Statement
ADC Stock Against Markets
ADC Therapeutics Corporate Directors
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Thomas Pfisterer | Non-Executive Independent Director | Profile | |
| Tyrell Rivers | Non-Executive Independent Director | Profile | |
| Peter Hug | Non-Executive Independent Director | Profile |
Already Invested in ADC Therapeutics SA?
The danger of trading ADC Therapeutics SA is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.